Distal administration of very high doses of intracoronary adenosine for the treatment of resistant no-reflow

Experimental and Clinical Cardiology

Volumn 13, Issue 3, 2008, Pages 141-146

  Movahed, Mohammad Reza ^a   Baweja, Gurpreet ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Adenosine; Balloon angioplasty; Complications; No reflow; Percutaneous coronary intervention; PTCA; Stenting

Indexed keywords

ADENOSINE; EPTIFIBATIDE; GLYCERYL TRINITRATE; HEPARIN; NITROPRUSSIDE SODIUM;

AGED; ARTICLE; ARTIFICIAL HEART PACEMAKER; BALLOON CATHETER; BLOOD PRESSURE; CASE REPORT; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION ROUTE; DRUG MEGADOSE; DRUG TOLERABILITY; HEART ARREST; HEART CATHETERIZATION; HEART INFARCTION; HUMAN; INTRACORONARY DRUG ADMINISTRATION; MALE; NO REFLOW PHENOMENON; POSTOPERATIVE COMPLICATION; SINGLE DRUG DOSE; ST SEGMENT ELEVATION; THROMBECTOMY;

EID: 55349089909     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994;89:2514-8.
2. Vallejo E, Peña-Duque MA, Noroño O, et al. [The no-reflow phenomenon: Its incidence and clinical characteristics in a series of cases]. Arch Inst Cardiol Mex 1998;68:247-52.
3. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: A review of mechanisms and therapies. Eur Heart J 2001;22:729-39.
4. Costantini CO, Stone GW, Mehran R, et al. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa. inhibition, in acute myocardial infarction. J Am Coll Cardiol 2004;44:305-12.
5. Taniyama Y, Ito H, Iwakura K, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997;30:1193-9.
6. Jennings RB, Ganote CE, Kloner RA, Whalen DA Jr, Hamilton DG. Explosive swelling of myocardial cells irreversibly injured by transient ischemia. Recent Adv Stud Cardiac Struct Metab 1975;6:405-13.
7. Fugit MD, Rubal BJ, Donovan DJ. Effects of intracoronary nicardipine, diltiazem and verapamil on coronary blood flow. J Invasive Cardiol 2000;12:80-5.
8. Abbo KM, Dooris M, Glazier S, et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol 1995;75:778-82.
9. Resnic FS, Wainstein M, Lee MK, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 2003;145:42-6.
10. Movahed MR, Balian H, Moraghebi P. Reversible severe ischemic mitral regurgitation and cardiogenic shock as a complication of percutaneous coronary intervention. J Invasive Cardiol 2005;17:104-7.
11. Lee CH, Wong HB, Tan HC, et al. impact of reversibility of no reflow phenomenon on 30-day mortality following percutaneous revascularization for acute myocardial infarction - insights from a 1,328 patient registry. J Interv Cardiol 2005;18:261-6.
12. Klein LW, Kern MJ, Berger P et al. Society of cardiac angiography and interventions: Suggested management of the no-reflow phenomenon in the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2003;60:194-201.
13. Kaplan BM, Benzuly KH, Kinn JW, et al. Treatment of no-reflow in degenerated saphenous vein graft interventions: Comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn 1996;39:113-8.
14. Michaels AD, Appleby M, Otten MH, et al. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: Results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. J Invasive Cardiol 2002;14:299-302.
15. Pasceri V, Pristipino C, Pelliccia F, et al. Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am J Cardiol 2005;95:1358-61.
16. Fischell TA, Carter AJ, Foster MT, et al. Reversal of "no reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet Cardiovase Diagn 1998;45:360-5.
17. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000;101:2154-9.
18. Skelding KA, Goldstein JA, Mehra L, Pica MC, O'Neill WW. Resolution of refractory no-reflow with intracoronary epinephrine. Catheter Cardiovasc Interv 2002;57:305-9.
19. Claeys MJ, Bosmans J, De Ceuninck M, et al. Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction. Am J Cardiol 2004;94:9-13.
20. Saito T, Hokimoto S, Ishibashi F Noda K, Oshima S. Pulse infusion thrombolysis (PIT) for large intracoronary thrombus: Preventive effect against the 'no flow' phenomenon in revascularization therapy for acute myocardial infarction. Jpn Circ J 2001;65:94-8.
21. Herrmann HC, Moliterno DJ, Ohman EM, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: Results from the SPEED (GUSTO-4 Pilot) Trial. J Am Coll Cardiol 2000;36:1489-96.
22. Barcin C, Denktas AE, Lennon RJ, et al. Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon. Catheter Cardiovasc Interv 2004;61:484-91.
23. Lim SY, Bae EH, Jeong MH, et al. Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention. Circ J 2004;68:928-32.
24. Dillon WC, Hadian D, Ritchie ME. Refractory no-reflow successfully treated with local infusion of high-dose adenosine and verapamil - +a case report. Angiology 2001;52:137-41.
25. Demir I, Yilmaz H, Ermis C, Sancaktar O. Treatment of no-reflow phenomenon with verapamil after primary stent deployment during myocardial infarction. Jpn Heart J 2002;43:573-80.